We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.53B
AUM Growth
+$567M
Cap. Flow
+$2.93M
Cap. Flow %
0.04%
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$20.9M
2
INCY icon
Incyte
INCY
+$16.3M
3
ISRG icon
Intuitive Surgical
ISRG
+$14.4M
4
DXCM icon
DexCom
DXCM
+$14.1M
5
CNC icon
Centene
CNC
+$13.5M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$40.9M
2
UNH icon
UnitedHealth
UNH
+$38.4M
3
ELV icon
Elevance Health
ELV
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
51
Fate Therapeutics
FATE
$332M
$49.1M 0.65%
4,861,279
+1,115,193
+30% +$20.9M
MDT icon
52
Medtronic
MDT
$106B
$48.1M 0.64%
618,420
+2,494
+0.4% +$202K
BIO icon
53
Bio-Rad Laboratories Class A
BIO
$8.04B
$46.7M 0.62%
111,158
+9,340
+9% +$3.77M
HALO icon
54
Halozyme
HALO
$9.3B
$46.2M 0.61%
812,700
-117,800
-13% -$6.03M
TMO icon
55
Thermo Fisher Scientific
TMO
$196B
$45.9M 0.61%
83,329
+11,185
+16% +$5.93M
IDXX icon
56
Idexx Laboratories
IDXX
$44.6B
$44.4M 0.59%
108,822
– –
EXEL icon
57
Exelixis
EXEL
$14.1B
$42.9M 0.57%
2,673,500
– –
TMDX icon
58
Transmedics
TMDX
$2.5B
$42.1M 0.56%
682,058
+28,244
+4% +$1.5M
PFE icon
59
Pfizer
PFE
$143B
$40.4M 0.54%
788,673
+21,373
+3% +$1.02M
IQV icon
60
IQVIA
IQV
$34B
$37.6M 0.5%
183,320
+23,093
+14% +$4.68M
CRSP icon
61
CRISPR Therapeutics
CRSP
$4.73B
$37.1M 0.49%
911,705
-16,600
-2% -$881K
CDNA icon
62
CareDx
CDNA
$2.01B
$36.2M 0.48%
3,168,448
+567,002
+22% +$8.4M
ZBH icon
63
Zimmer Biomet
ZBH
$17.6B
$34M 0.45%
266,296
+1,026
+0.4% +$119K
AXSM icon
64
Axsome Therapeutics
AXSM
$11.9B
$33.7M 0.45%
436,658
-59,866
-12% -$3.58M
BNTX icon
65
BioNTech
BNTX
$23.1B
$33.2M 0.44%
221,080
+67,500
+44% +$10.4M
HRMY icon
66
Harmony Biosciences
HRMY
$1.98B
$32.9M 0.44%
596,192
-60,996
-9% -$3.35M
WVE icon
67
Wave Life Sciences
WVE
$1.14B
$31.5M 0.42%
4,494,458
– –
PRCT icon
68
Procept Biorobotics
PRCT
$1.08B
$30.8M 0.41%
741,517
+152,255
+26% +$6.54M
VEEV icon
69
Veeva Systems
VEEV
$31.2B
$30.1M 0.4%
186,257
+28,666
+18% +$4.9M
ACCD
70
DELISTED
Accolade Inc
ACCD
$28.6M 0.38%
3,677,277
+105,407
+3% +$1.01M
ATRC icon
71
AtriCure
ATRC
$1.75B
$28.6M 0.38%
644,109
+1,662
+0.3% +$69.4K
HCM icon
72
HUTCHMED
HCM
$1.93B
$28.4M 0.38%
1,780,144
+22,069
+1% +$241K
BEAM icon
73
Beam Therapeutics
BEAM
$2.85B
$27.2M 0.36%
696,721
+125,000
+22% +$5.6M
ESPR
74
DELISTED
Esperion Therapeutics
ESPR
$27M 0.36%
4,330,264
+105,000
+2% +$751K
COO icon
75
Cooper Companies
COO
$13.9B
$26.9M 0.36%
325,252
– –
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2022 Portfolio in Review

As of Q4 2022, Bellevue Group held 184 positions worth $7.53B, up 8.1% from $6.97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group's Q4 2022 filing shows 8 new, 71 increased, 51 reduced and 13 closed positions. Its largest new stake was Natera: 173,812 shares worth $6.98M. The largest sale was Abiomed Inc, an estimated $40.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q4 2022 buy was Natera: 173,812 shares worth $6.98M.
  • Bellevue Group added most to Fate Therapeutics in Q4 2022, an estimated $20.9M increase.
  • Bellevue Group's biggest Q4 2022 reduction was UnitedHealth, cutting an estimated $38.4M.
  • Bellevue Group fully exited Abiomed Inc in Q4 2022, selling an estimated $40.9M.
  • Bellevue Group's ten largest holdings make up 36% of its $7.53B portfolio in Q4 2022.
  • Bellevue Group opened 8 new positions and closed 13 in Q4 2022.
  • Bellevue Group's portfolio value rose 8.1% quarter-over-quarter to $7.53B.

Based on Bellevue Group's 13F filing for Q4 2022, filed 14 Feb 2023.